Skip to Main Content

Paper Details

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
J Thorac Oncol
20
2023
APOBEC mutational, Advanced, EGFR, EGFR-Mutant Lung Cancers, EGFR-mutant lung cancer, MET, Osimertinib, Patients, RB1, TP53, metastatic, metastatic EGFR-mutant lung cancer, osimertinib, patient, patients, small cell lung transformation, tumor, tumors
Author NameAffiliation
Pier SelenicaMemorial Sloan Kettering Cancer Center
Daniel R GomezMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center, New York Marie-Josee and Henry R. Kravis Center for Molecular Oncology
Marc LadanyiMemorial Sloan Kettering Cancer Center, New York Marie-Josee and Henry R. Kravis Center for Molecular Oncology
Charles M RudinMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Gregory J RielyMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
  • 1 - 7

Datasets

Release 1.2